Independent prognostic impact of plasma NCOA2 alterations in metastatic castration‐resistant prostate cancer

The Prostate ◽  
2021 ◽  
Author(s):  
Heidi Fettke ◽  
Edmond M. Kwan ◽  
Patricia Bukczynska ◽  
Jason A. Steen ◽  
Maria Docanto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Impact ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer

2014 ◽  
Vol 12 (5) ◽  
pp. 317-324 ◽  
Author(s):  
Guru Sonpavde ◽  
Gregory R. Pond ◽  
Andrew J. Armstrong ◽  
Stephen J. Clarke ◽  
Janette L. Vardy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
Prognostic Impact ◽  
Castration Resistant Prostate Cancer ◽  
Lymphocyte Ratio ◽  
Castration Resistant

Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer

2019 ◽  
Vol 49 (11) ◽  
pp. 1043-1048 ◽  
Author(s):  
Kent Kanao ◽  
Toshiki Ito ◽  
Kiyoshi Takahara ◽  
Ryosuke Ando ◽  
Takahiro Yasui ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Prognostic Impact ◽  
Response Patterns ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Oncology Research ◽  
Number Of Patients ◽  
Psa Response

Abstract Background The objective of this study was to categorize prostate-specific antigen (PSA) response during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) into different patterns and to investigate the prognostic impact of the PSA response patterns. Methods We reviewed data from patients with mCRPC who had been treated with cabazitaxel therapy at four institutions belonging to Tokai Urologic Oncology Research Seminar. Patients eligible for this study had received at least three cycles of cabazitaxel treatment at three- or four-week intervals. The PSA response patterns were categorized as primary resistance (PR), response (RE), stabilization (ST), and fluctuating (FL). The overall survival (OS) was compared among the patterns. Results Data from a total of 50 patients were analyzed in this study. The number of patients exhibiting PR, RE, ST and FL patterns were 18 (36%), 14 (28%), 12 (24%) and 6 (12%), respectively. The median (95% CI) OS of patients with PR and RE patterns was 10.7 (5.6–15.9) and 14.9 (6.8–23.0) months, respectively, and was not reached for patients with ST and FL patterns. The OS of patients with the FL pattern was significantly better than that of patients with PR (P = 0.012) and RE (P = 0.010) patterns. Conclusion There were some patients whose PSA were fluctuating during cabazitaxel therapy in patients with mCRPC. Because the prognosis of such patients was relatively good, the judgment to discontinue the cabazitaxel therapy after PSA rise followed by decrease should be made prudently.

Sign in / Sign up

Export Citation Format

Share Document